Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
Hum Vaccin Immunother
; 11(3): 620-31, 2015.
Article
em En
| MEDLINE
| ID: mdl-25715157
Palavras-chave
AEs; Accordingto-Protocol; CIs; Confidence Intervals; ClfA; Panton-Valentine leucocidin; rEPA; Staphylococcus aureus; adjuvant; adverse events; AT; capsular polysaccharides types 5 and 8; GMC; clumping factor A; CPS5 and 8; geometric mean concentration; GMT; geometric mean titer; ICS; immunogenicity; interferon; IL; interleukin; LNR; intracellular cytokine staining; IFN; laboratory normal range; MRSA; methicillin-resistant S. aureus; OPA; opsonophagocytic assay; pIMDs; potential immune-mediated diseases: PVL; recombinant exoprotein A from Pseudomonas aeruginosa; SAEs; safety; serious adverse events; TT; tetanus toxoid; vaccine; α-toxin; ATP
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções Estafilocócicas
/
Vacinas Antiestafilocócicas
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Idioma:
En
Revista:
Hum Vaccin Immunother
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Bélgica